Create an alert
Stocks and Shares ISAOvoca Bio PLC is a clinical-stage biopharmaceutical company focused on women’s health. The Company is developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). It is focused on women’s health and identifying novel candidates in areas of high unmet medical need. The Company’s lead product, Orenetide (BP-101), is a novel synthetic peptide for the treatment of HSDD and is conveniently administered through a nasal spray. The spray delivers the drug to olfactory and trigeminal nerves in the nasal cavity where the drug accumulates in the olfactory bulb and further in the brain.
Ovoca Bio Plc (OVB) Euro 0.125
Sell:1.15pBuy:1.15p
No change
Prices delayed by at least 15 minutes
- This stock can be held in a
Sell:1.15p
Buy:1.15p
Change:No change
No changePrices delayed by at least 15 minutes
Sell:1.15p
Buy:1.15p
Change:No change
No changePrices delayed by at least 15 minutes
Company Information
About this company
Key people
Timothy Rand Mccutcheon
Chief Executive Officer, Director
Leah O'donovan
Chief Financial Officer
Dmitriy Nikitashenko
Vice President - Finance
Reneta Nikolova
Company Secretary
Leonid Pavlovich Skoptsov
Non-Executive Director
Anastasia Levashova
Non-Executive Independent Director
Kristina Zakurdaeva
Non-Executive Independent Director
Click to see more
Key facts
- Shares in issue88.46m
- EPICOVB
- ISINIE00B4XVDC01
- LocationIreland
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap£937,984.00
- Employees1
- ExchangeLondon Stock Exchange (LON)
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.